Mechanisms of immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 6, 2004, Pages 1025-1034

  Till, Stephen J ^a   Francis, James N ^a   Nouri Aria, Kayhan ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

allergy; IgE; IL 10; Immunoreceptor tyrosine based inhibition motif; Immunotherapy; ITIM; Monophosphoryl lipid A; MPL; regulatory T cells

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; PEPTIDE DERIVATIVE; PHOSPHORYL LIPID A;

ALLERGIC RHINITIS; ALLERGY; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BASOPHIL; CYTOKINE PRODUCTION; DENDRITIC CELL; EOSINOPHIL; HISTAMINE RELEASE; HUMAN; IMMUNOTHERAPY; INJECTION SITE; MAST CELL; NUCLEOTIDE SEQUENCE; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL;

ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN-10; T-LYMPHOCYTES;

EID: 3042708626     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.03.024     Document Type: Review

References (82)

1. Bousquet J., Lockey R., Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 102:1998;558-562
2. Lockey R.F. "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol. 108:2001;497-499
3. Varney V.A., Gaga M., Frew A.J., Aber V.R., Kay A.B., Durham S.R. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 302:1991;265-269
4. Walker S.M., Pajno G.B., Lima M.T., Wilson D.R., Durham S.R. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 107:2001;87-93
5. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 341:1999;468-475
6. Golden D.B., Kwiterovich K.A., Kagey-Sobotka A., Valentine M.D., Lichtenstein L.M. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 97:1996;579-587
7. Pajno G.B., Barberio G., De Luca F., Morabito L., Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 31:2001;1392-1397
8. Moller C., Dreborg S., Ferdousi H.A., Halken S., Host A., Jacobsen L., et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 109:2002;251-256
9. Secrist H., DeKruyff R.H., Umetsu D.T. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med. 181:1995;1081-1089
10. Kapsenberg M.L., Hilkens C.M., Wierenga E.A., Kalinski P. The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy. Clin Exp Allergy. 29:(suppl 2):1999;33-36
11. Reider N., Reider D., Ebner S., Holzmann S., Herold M., Fritsch P., et al. Dendritic cells contribute to the development of atopy by an insufficiency in IL-12 production. J Allergy Clin Immunol. 109:2002;89-95
12. Gehlhar K., Schlaak M., Becker W., Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy. 29:1999;497-506
13. Lichtenstein L.M., Ishizaka K., Norman P.S., Sobotka A.K., Hill B.M. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 52:1973;472-482
14. Moverare R., Elfman L., Vesterinen E., Metso T., Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 57:2002;423-430
15. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 33:2003;1205-1214
16. Muller U., Akdis C.A., Fricker M., Akdis M., Blesken T., Bettens F., et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 101:1998;747-754
17. Garcia B.E., Sanz M.L., Gato J.J., Fernandez J., Oehling A. IgG4 blocking effect on the release of antigen-specific histamine. J Investig Allergol Clin Immunol. 3:1993;26-33
18. van Neerven R.J., Wikborg T., Lund G., Jacobsen B., Brinch-Nielsen A., Arnved J., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol. 163:1999;2944-2952
19. Wachholz P.A., Soni N.K., Till S.J., Durham S.R. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 112:2003;915-922
20. Daeron M., Malbec O., Latour S., Arock M., Fridman W.H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest. 95:1995;577-585
21. Malbec O., Fong D.C., Turner M., Tybulewicz V.L., Cambier J.C., Fridman W.H., et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol. 160:1998;1647-1658
22. Zhu D., Kepley C.L., Zhang M., Zhang K., Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med. 8:2002;518-521
23. Ewan P.W., Deighton J., Wilson A.B., Lachmann P.J. Venom-specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings. Clin Exp Allergy. 23:1993;647-660
24. Djurup R., Malling H.J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy. 17:1987;459-468
25. Michils A., Mairesse M., Ledent C., Gossart B., Baldassarre S., Duchateau J. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J Allergy Clin Immunol. 102:1998;118-126
26. Michils A., Baldassarre S., Ledent C., Mairesse M., Gossart B., Duchateau J. Early effect of ultrarush venom immunotherapy on the IgG antibody response. Allergy. 55:2000;455-462
27. Kolbe L., Heusser C.H., Kolsch E. Isotype-associated recognition of allergen epitopes and its modulation by antigen dose. Immunology. 84:1995;285-289
28. Jutel M., Pichler W.J., Skrbic D., Urwyler A., Dahinden C., Muller U.R. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol. 154:1995;4187-4194
29. Akdis C.A., Akdis M., Blesken T., Wymann D., Alkan S.S., Muller U., et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest. 98:1996;1676-1683
30. Ebner C., Siemann U., Bohle B., Willheim M., Wiedermann U., Schenk S., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy. 27:1997;1007-1015
31. Eusebius N.P., Papalia L., Suphioglu C., McLellan S.C., Varney M., Rolland J.M., et al. Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (Bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol. 127:2002;234-244
32. Secrist H., Chelen C.J., Wen Y., Marshall J.D., Umetsu D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med. 178:1993;2123-2130
33. Till S., Walker S., Dickason R., Huston D., O'Brien F., Lamb J., et al. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol. 110:1997;114-121
34. Wachholz P.A., Nouri-Aria K.T., Wilson D.R., Walker S.M., Verhoef A., Till S.J., et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology. 105:2002;56-62
35. Francis J.N., Till S.J., Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 111:2003;1255-1261
36. Bellinghausen I., Metz G., Enk A.H., Christmann S., Knop J., Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 27:1997;1131-1139
37. Akdis C.A., Blesken T., Akdis M., Wuthrich B., Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 102:1998;98-106
38. Francis J.N., Jacobson M.R., Lloyd C.M., Sabroe I., Durham S.R., Till S.J. CXCR1+CD4+ T cells in human allergic disease. J Immunol. 172:2004;268-273
39. Varney V.A., Hamid Q.A., Gaga M., Ying S., Jacobson M., Frew A.J., et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 92:1993;644-651
40. Varga E.M., Wachholz P., Nouri-Aria K.T., Verhoef A., Corrigan C.J., Till S.J., et al. T cells from human allergen-induced late asthmatic responses express IL-12 receptor beta 2 subunit mRNA and respond to IL-12 in vitro. J Immunol. 165:2000;2877-2885
41. Hamid Q.A., Schotman E., Jacobson M.R., Walker S.M., Durham S.R. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 99:1997;254-260
42. Durham S.R., Ying S., Varney V.A., Jacobson M.R., Sudderick R.M., Mackay I.S., et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 97:1996;1356-1365
43. Wilson D.R., Nouri-Aria K.T., Walker S.M., Pajno G.B., O'Brien F., Jacobson M.R., et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol. 107:2001;971-976
44. Klimek L., Dormann D., Jarman E.R., Cromwell O., Riechelmann H., Reske-Kunz A.B. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy. 29:1999;1326-1335
45. Nouri-Aria K.T., Wachholz P.A., Francis J.N., Jacobson M.R., Walker S.M., Wilcock L.K., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 172:2004;3252-3259
46. Nasser S.M., Ying S., Meng Q., Kay A.B., Ewan P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol. 31:2001;3704-3713
47. Gaglani B., Borish L., Bartelson B.L., Buchmeier A., Keller L., Nelson H.S. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol. 79:1997;259-265
48. Akdis C.A., Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13:1999;603-609
49. Akdis C.A., Joss A., Akdis M., Faith A., Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J. 14:2000;1666-1668
50. Larche M., Till S.J., Haselden B.M., North J., Barkans J., Corrigan C.J., et al. Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. J Immunol. 16:1998;6375-6382
51. Flores-Villanueva P.O., Zheng X.X., Strom T.B., Stadecker M.J. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol. 156:1996;3315-3320
52. Kingsley C.I., Karim M., Bushell A.R., Wood K.J. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 168:2002;1080-1086
53. Quattrocchi E., Dallman M.J., Dhillon A.P., Quaglia A., Bagnato G., Feldmann M. Murine IL-10 gene transfer inhibits established collagen-induced arthritis and reduces adenovirus-mediated inflammatory responses in mouse liver. J Immunol. 166:2001;5970-5978
54. Cua D.J., Hutchins B., LaFace D.M., Stohlman S.A., Coffman R.L. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol. 166:2001;602-608
55. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:1997;737-742
56. Tournoy K.G., Kips J.C., Pauwels R.A. Endogenous interleukin-10 suppresses allergen-induced airway inflammation and nonspecific airway responsiveness. Clin Exp Allergy. 30:2000;775-783
57. Akbari O., DeKruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2:2001;725-731
58. Bellinghausen I., Knop J., Saloga J. The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol. 126:2001;97-101
59. Jeannin P., Lecoanet S., Delneste Y., Gauchat J.F., Bonnefoy J.Y. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 160:1998;3555-3561
60. Royer B., Varadaradjalou S., Saas P., Guillosson J.J., Kantelip J.P., Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy. 31:2001;694-704
61. Takanaski S., Nonaka R., Xing Z., O'Byrne P., Dolovich J., Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med. 180:1994;711-715
62. Akbari O., Stock P., DeKruyff R.H., Umetsu D.T. Role of regulatory T cells in allergy and asthma. Curr Opin Immunol. 15:2003;627-633
63. Akbari O., Freeman G.J., Meyer E.H., Greenfield E.A., Chang T.T., Sharpe A.H., et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 8:2002;1024-1032
64. Bellinghausen I., Brand U., Steinbrink K., Enk A.H., Knop J., Saloga J. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol. 108:2001;242-249
65. Muller G., Muller A., Tuting T., Steinbrink K., Saloga J., Szalma C., et al. Interleukin-10-treated dendritic cells modulate immune responses of naive and sensitized T cells in vivo. J Invest Dermatol. 119:2002;836-841
66. McGuirk P., McCann C., Mills K.H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med. 195:2002;221-231
67. Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 192:2000;1213-1222
68. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 193:2001;233-238
69. Curotto de Lafaille M.A., Lafaille J.J. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol. 14:2002;771-778
70. Nopp A., Hallden G., Lundahl J., Johansson E., Vrtala S., Valenta R., et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol. 106:2000;101-109
71. Hage-Hamsten M., Johansson E., Roquet A., Peterson C., Andersson M., Greiff L., et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy. 32:2002;1448-1453
72. Norman P.S., Ohman J.L. Jr., Long A.A., Creticos P.S., Gefter M.A., Shaked Z., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 154:1996;1623-1628
73. Oldfield W.L., Larche M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 360:2002;47-53
74. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol. 168:2002;926-932
75. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 347:2002;1652-1661
76. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 56:2001;498-505
77. Bohle B., Jahn-Schmid B., Maurer D., Kraft D., Ebner C. Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 29:1999;2344-2353
78. Broide D., Schwarze J., Tighe H., Gifford T., Nguyen M.D., Malek S., et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 161:1998;7054-7062
79. Tighe H., Takabayashi K., Schwartz D., Van Nest G., Tuck S., Eiden J.J., et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 106:2000;124-134
80. Marshall J.D., Abtahi S., Eiden J.J., Tuck S., Milley R., Haycock F., et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 108:2001;191-197
81. Santeliz J.V., Van Nest G., Traquina P., Larsen E., Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol. 109:2002;455-462
82. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 113:2004;235-241